EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 9 November 2023

How would the proposed EU Pharma Legislation affect Europe's competitiveness?

Discover more.

A study from Dolon, commissioned by EFPIA, shows that the Commission’s plans could accelerate Europe's decline in innovation compared to the USA, China, and Japan. This could result in:

A one-third reduction in Europe's share of global R&D investment by 2040, dropping from 32% to 21%.
Loss of one in five medicines in development (22%) which would no longer be economically viable in Europe.
A loss of 16 million years of life lost (YLL) due to increased mortality and premature death across the EU.

Regaining lost ground: It’s time for a future-oriented pharmaceutical policy

"Europe must take back its leadership and develop a long-term strategy and policies to regain, sustain, and develop life sciences in Europe."

Check out what Peter Guenter, CEO of Healthcare at Merck, has written on POLITICO.

Blogs

Improving men's health standards in Europe: a vital need for action (Guest blog)
07 November 2023 - Jacqueline Daly - Phil Reynolds

As #Movember kicks off, we turn to two experts from the Let’s Talk Prostate Cancer (LTPC) Expert Group to shed light... Read more

Listen to Christian Schneider on how an improved regulatory environment could benefit competitiveness

In this podcast, we discuss the continuing challenges to Europe’s Biopharma competitiveness, and how an improved regulatory environment could be a benefit. Christian also highlights both the risks and opportunities of the EU’s proposed revision of the general pharmaceutical legislation.

This podcast was developed in collaboration with Vital Transformation.

It's #MedSafetyWeek!

Join the discussion to help us spread the word about reporting side effects.

What we are reading

Patient involvement in HTA in Europe
On 01 November 2023 (HTAi)

Recommendations from a 360° perspective view of current patient involvement practices.

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
On 02 November 2023 (OHE)

New antibiotics are urgently needed, but their development is hindered by market failure. A 'volume-delinked model'... Read more

RADIAL has recruited its first remote patient
On 03 November 2023 (Trials@Home)

This means that they have a first patient that will conduct the clinical trial fully remote, @home without going... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu